通过下一代测序技术，内镜超声（EUS）在胰腺癌精准医学时代的作用
Role of Endoscopic Ultrasound (EUS) in the Era of Precision Medicine for Pancreatic Cancer Through Next-Generation Sequencing Technology.
作者信息
Peserico Giulia, Stornello Caterina, Tessari Martina, Scapinello Antonio, Curtarello Matteo, Gruppo Mario, De Simoni Ottavia, Fantin Alberto
机构信息
Gastroenterology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy.
Division of Gastroenterology, Department of Surgical, Oncological and Gastroenterological Sciences, Azienda Ospedaliera-Università di Padova, 35128 Padova, Italy.
出版信息
Int J Mol Sci. 2025 Aug 30;26(17):8444. doi: 10.3390/ijms26178444.
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a dismal prognosis; this is in part due to its late diagnosis at advanced stages. For many patients, medical treatment is the only practicable therapy. In recent years, the development of new technologies that investigate genomic biomarkers has improved the concept of precision medicine to treat patients with PDAC. Through endoscopic ultrasound-tissue acquisition (EUS-TA), tissue from pancreatic cancers can be collected; thus, it has the potential to advance personalized treatment by allowing the assessment of genomic alterations. In this review, we explore the role of EUS in genomic profiling and its strengths and pitfalls in obtaining samples for next-generation sequencing (NGS).
胰腺导管腺癌（PDAC）是一种预后极差的致命性疾病；部分原因在于其在晚期才被诊断出来。对许多患者而言，药物治疗是唯一可行的疗法。近年来，研究基因组生物标志物的新技术发展完善了治疗PDAC患者的精准医学概念。通过内镜超声组织采集（EUS-TA），可以收集胰腺癌组织；因此，它有潜力通过评估基因组改变来推进个性化治疗。在本综述中，我们探讨了EUS在基因组分析中的作用及其在获取用于下一代测序（NGS）样本方面的优势和缺陷。
Zotero 插件